Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callNasdaq· January 16, 2026

Aehr Test (AEHR) Q2 2026 Earnings Call Transcript

View original at nasdaq.com
Aehr Test (AEHR) Q2 2026 Earnings Call Transcript Image source: The Motley Fool. DATE Thursday, January 8, 2026 at 5:00 p.m…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Single AI processor wafer-level testing requires 20-30 systems at $4M-$5M each

    80% confidence
  • Testing and burning-in full wafers of GaN power semiconductors with up to 600 volts or more is not easy

    80% confidence
  • Lead Sonoma production customer provided very large forecast with shipments expected to start Q1 FY2027

    80% confidence
  • AI test and burn-in spending is currently $8B to $15B

    80% confidence
  • Aehr is not profitable at current revenue levels

    80% confidence
  • Aehr is the leading provider for HTOL testing of AI processors in test houses worldwide

    80% confidence
  • High Bandwidth Flash (HBF) development would take 1+ year after customer commitment

    80% confidence
  • Bookings forecast of $60M to $80M for second half FY2026 based on customer forecasts recently provided to Aehr

    80% confidence
  • The AI business opportunity for Aehr Test can be measured in hundreds of millions of dollars within a few years

    80% confidence
  • Aehr production capacity exceeds 20 systems per month at either package or wafer level, and can ship 20 per month of each if needed

    80% confidence
  • At least one customer is transitioning HTOL to production in late calendar 2026

    80% confidence
  • WaferPak design turnaround time is 8 weeks with Design for Test (DFT) lower pin count modes

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com